


## Hsp90-IN-15

Cat. No.:	HY-150655
CAS No.:	2252283-32-0
Molecular Formula:	C <sub>23</sub> H <sub>27</sub> F <sub>3</sub> N <sub>4</sub>
Molecular Weight:	416.48
Target:	HSP
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Hsp90-IN-15 is an Hsp90 inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of Hsp90 in HeLa cell <sup>[1]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	HSP90																
<b>In Vitro</b>	<p>Hsp90-IN-15 (compound 22g) againsts HeLa, HepG2, and MDA-MB-23 cells with IC<sub>50</sub>s of 19.6 μM, 16.1 μM, and 22.1 μM, respectively<sup>[1]</sup>.</p> <p>Hsp90-IN-15 binds with Hsp90<sup>N</sup>, and the ΔT<sub>m</sub> value is 10.92 °C<sup>[1]</sup>.</p> <p>Hsp90-IN-15 (0-20 μM; 48 h) arrests cell cycle at S phase in a dose-dependent manner<sup>[1]</sup>.</p> <p>Hsp90-IN-15 (0-20 μM; 48 h) exhibits an accumulation of early and late apoptotic cells in a time and dose dependent manner<sup>[1]</sup>.</p> <p>Caspase-3 is an executioner caspase and modifies apoptosis proteins<sup>[1]</sup>.</p> <p>Hsp90-IN-15 (0-50 μM; 48 h) increases the expression of Bax and cleaved-caspase 3, as well as downregulates the levels of Bcl-2, pro-caspase 3 and Hsp90<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 5, 10, 20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Arrested cell cycle at S phase dose-dependently.</td> </tr> </table> <p>Apoptosis Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 5, 10, 20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Induced apoptosis in HeLa cells.</td> </tr> </table>	Cell Line:	HeLa cells	Concentration:	0, 5, 10, 20 μM	Incubation Time:	48 hours	Result:	Arrested cell cycle at S phase dose-dependently.	Cell Line:	HeLa cells	Concentration:	0, 5, 10, 20 μM	Incubation Time:	48 hours	Result:	Induced apoptosis in HeLa cells.
Cell Line:	HeLa cells																
Concentration:	0, 5, 10, 20 μM																
Incubation Time:	48 hours																
Result:	Arrested cell cycle at S phase dose-dependently.																
Cell Line:	HeLa cells																
Concentration:	0, 5, 10, 20 μM																
Incubation Time:	48 hours																
Result:	Induced apoptosis in HeLa cells.																

---

#### Western Blot Analysis<sup>[1]</sup>

Cell Line:	HeLa cells
Concentration:	0, 12.5, 25, 50 $\mu$ M
Incubation Time:	48 hours
Result:	Decreased the level of Hsp90 and increased the proportion of Bax/Bcl-2 as well.

---

#### REFERENCES

[1]. Xu Y, et al. New modification strategy of matrine as Hsp90 inhibitors based on its specific L conformation for cancer treatment. Bioorg Med Chem. 2020 Feb 15. 28(4):115305.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA